Argentarii LLC Acquires New Holdings in AstraZeneca PLC (NASDAQ:AZN)

Argentarii LLC acquired a new stake in shares of AstraZeneca PLC (NASDAQ:AZN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 3,483 shares of the company’s stock, valued at approximately $228,000.

Several other hedge funds also recently bought and sold shares of the company. Capital Performance Advisors LLP bought a new stake in AstraZeneca during the third quarter valued at approximately $28,000. Ashton Thomas Securities LLC bought a new stake in AstraZeneca during the third quarter valued at approximately $45,000. Albion Financial Group UT lifted its position in AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after purchasing an additional 248 shares during the last quarter. Versant Capital Management Inc lifted its position in AstraZeneca by 2,618.5% during the fourth quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock valued at $48,000 after purchasing an additional 707 shares during the last quarter. Finally, Golden State Wealth Management LLC bought a new stake in AstraZeneca during the fourth quarter valued at approximately $55,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Trading Up 0.0 %

Shares of AZN opened at $77.50 on Monday. The firm has a market cap of $240.34 billion, a price-to-earnings ratio of 34.29, a PEG ratio of 1.42 and a beta of 0.41. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. AstraZeneca PLC has a fifty-two week low of $62.75 and a fifty-two week high of $87.68. The firm has a 50 day moving average price of $70.83 and a 200-day moving average price of $72.65.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. As a group, equities research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Monday, March 24th. Investors of record on Friday, February 21st will be paid a $1.03 dividend. This represents a dividend yield of 2%. This is an increase from AstraZeneca’s previous semi-annual dividend of $0.49. The ex-dividend date of this dividend is Friday, February 21st. AstraZeneca’s payout ratio is presently 91.15%.

Analyst Ratings Changes

Several equities research analysts have issued reports on AZN shares. UBS Group upgraded shares of AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Thursday, February 13th. Morgan Stanley assumed coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They issued an “overweight” rating for the company. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.